Independent Drug Action in Combination Therapy: Implications for Precision Oncology

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Jan 5

PMID 34983746

Citations 71

Authors

Deborah Plana

Adam C Palmer

Peter K Sorger

Affiliations

Soon will be listed here.

Abstract

Significance: The model of independent drug action represents an effective means to predict the magnitude of benefit likely to be observed in new clinical trials for combination therapies. The "bet-hedging" strategy implicit in independent action suggests that individual patients often benefit from only a subset-sometimes one-of the drugs in a combination. Personalized, targeted combination therapy, consisting of agents likely to be active in a particular patient, will increase, perhaps substantially, the magnitude of therapeutic benefit. Precision approaches of this type will require a better understanding of variability in drug response and new biomarkers, which will entail preclinical research on diverse panels of cancer models rather than studying drug synergy in unusually sensitive models.

Citing Articles

Scaling up drug combination surface prediction.

Huusari R, Wang T, Szedmak S, Dias D, Aittokallio T, Rousu J Brief Bioinform. 2025; 26(2).

PMID: 40079263 PMC: 11904408. DOI: 10.1093/bib/bbaf099.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.

Rahjoo T, Motamedzadeh A, Ferdosi F, Dadgostar E, Aschner M, Mirzaei H Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40045027 DOI: 10.1007/s00210-025-03861-1.

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.

Discoidin domain receptor inhibitor DDR1-IN-1 induces autophagy and necroptotic cell death in malignant peripheral nerve sheath tumor.

Lai G, Lee Y, Weng H, Lai K, Hsiang M, Hsu K Cell Death Discov. 2025; 11(1):83.

PMID: 40025071 PMC: 11873111. DOI: 10.1038/s41420-025-02367-2.

References

Conlin A, Seidman A . Point: combination versus single-agent chemotherapy: the argument for sequential single agents. J Natl Compr Canc Netw. 2007; 5(8):668-72. DOI: 10.6004/jnccn.2007.0068. View

Doroshow D, Sanmamed M, Hastings K, Politi K, Rimm D, Chen L . Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019; 25(15):4592-4602. PMC: 6679805. DOI: 10.1158/1078-0432.CCR-18-1538. View

Sicklick J, Kato S, Okamura R, Patel H, Nikanjam M, Fanta P . Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021; 13(1):155. PMC: 8491393. DOI: 10.1186/s13073-021-00969-w. View

Ascierto P, Ferrucci P, Fisher R, Del Vecchio M, Atkinson V, Schmidt H . Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019; 25(6):941-946. DOI: 10.1038/s41591-019-0448-9. View

Fallahi-Sichani M, Becker V, Izar B, Baker G, Lin J, Boswell S . Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017; 13(1):905. PMC: 5248573. DOI: 10.15252/msb.20166796. View

Stockslager M, Malinowski S, Touat M, Yoon J, Geduldig J, Mirza M . Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep. 2021; 37(1):109788. DOI: 10.1016/j.celrep.2021.109788. View

Coussy F, El-Botty R, Chateau-Joubert S, Dahmani A, Montaudon E, Leboucher S . BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med. 2020; 12(531). PMC: 8662740. DOI: 10.1126/scitranslmed.aax2625. View

Pritchard J, Bruno P, Gilbert L, Capron K, Lauffenburger D, Hemann M . Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2012; 110(2):E170-9. PMC: 3545813. DOI: 10.1073/pnas.1210419110. View

Ianevski A, Timonen S, Kononov A, Aittokallio T, Giri A . SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. PLoS Comput Biol. 2020; 16(2):e1007604. PMC: 7018095. DOI: 10.1371/journal.pcbi.1007604. View

10.

Jonas O, Landry H, Fuller J, Santini Jr J, Baselga J, Tepper R . An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med. 2015; 7(284):284ra57. PMC: 4825177. DOI: 10.1126/scitranslmed.3010564. View

11.

Zhu Z, Liu W, Gotlieb V . The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2015; 99:91-9. DOI: 10.1016/j.critrevonc.2015.12.002. View

12.

Berge E, Lu X, Maxson D, Baron A, Gadgeel S, Solomon B . Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer. 2013; 14(6):636-43. PMC: 4126227. DOI: 10.1016/j.cllc.2013.06.005. View

13.

Pemovska T, Bigenzahn J, Superti-Furga G . Recent advances in combinatorial drug screening and synergy scoring. Curr Opin Pharmacol. 2018; 42:102-110. PMC: 6219891. DOI: 10.1016/j.coph.2018.07.008. View

14.

Chen C, Liu F, Ren Y, Suttner L, Sun Z, Shentu Y . Independent drug action and its statistical implications for development of combination therapies. Contemp Clin Trials. 2020; 98:106126. DOI: 10.1016/j.cct.2020.106126. View

15.

Fan W, Yung B, Huang P, Chen X . Nanotechnology for Multimodal Synergistic Cancer Therapy. Chem Rev. 2017; 117(22):13566-13638. DOI: 10.1021/acs.chemrev.7b00258. View

16.

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View

17.

Lin J, Izar B, Wang S, Yapp C, Mei S, Shah P . Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018; 7. PMC: 6075866. DOI: 10.7554/eLife.31657. View

18.

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

19.

Nowakowski G, Feldman T, Rimsza L, Westin J, Witzig T, Zinzani P . Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J. 2019; 9(6):48. PMC: 6522601. DOI: 10.1038/s41408-019-0208-6. View

20.

Kuenzi B, Park J, Fong S, Sanchez K, Lee J, Kreisberg J . Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell. 2020; 38(5):672-684.e6. PMC: 7737474. DOI: 10.1016/j.ccell.2020.09.014. View